Apo2L/TRAIL and immune regulation.
Apo2L/TRAIL is a member of the TNF family, with its receptors DR4 and DR5 containing a death domain. Multiple tumors are sensitive to Apo2L/TRAIL-induced apoptosis, while normal cells are not, so it constitutes a promising new antitumoral therapy. In this review we deal rather with the physiological role of Apo2L/TRAIL, which, in one hand, is clearly related with immune antitumoral surveillance. However, a role of Apo2L/TRAIL as a fine-tuning regulator of the immune system, especially in the regulation of CD8+ T cell activation and memory, has been also demonstrated. In fact, Apo2L/TRAIL can be considered as an additional mechanism needed to prevent the development of autoimmune disease. Indeed, recent developments indicate that Apo2L/TRAIL can be also useful as a treatment against certain chronic autoimmune diseases.
Anel
Alberto
A
Department of Biochemistry and Molecular and Cellular Biology, Faculty of Sciences, University of Zaragoza, Spain. anel@posta.unizar.es
Bosque
Alberto
A
Naval
Javier
J
Pineiro
Andres
A
Larrad
Luis
L
Alava
Maria Angeles
MA
Martinez-Lorenzo
Maria Jose
MJ
D000818:Animals; D017209:Apoptosis; D001327:Autoimmune Diseases / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D008213:Lymphocyte Activation; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000502:physiology*
D053221:TNF-Related Apoptosis-Inducing Ligand